Upregulation of fractalkine contributes to the proliferative response of prostate cancer cells to hypoxia via promoting the G1/S phase transition

Molecular Medicine Reports

Volumn 12, Issue 6, 2015, Pages 7907-7914

  Tang, Jiebing ^a   Chen, Yuanyuan ^a   Cui, Rongjun ^b   Li, Dong ^a   Xiao, Lijie ^a   Lin, Ping ^a   Du, Yandan ^c   Sun, Hui ^a,c   Yu, Xiaoguang ^a   Zheng, Xiulan ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b MUDANJIANG MEDICAL UNIVERSITY   (China)

^c INNER MONGOLIA UNIVERSITY FOR NATIONALITIES   (China)

Author keywords

Cell cycle; DU145 cells; Fractalkine; Hypoxia; Proliferation

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN E; FRACTALKINE; MESSENGER RNA;

ARTICLE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL HYPOXIA; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MALE; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CX3CL1; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATIC NEOPLASMS; TUMOR MICROENVIRONMENT; UP-REGULATION;

EID: 84946771413     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4438     Document Type: Article

References (39)

1. Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin 64: 9-29, 2014.
2. Baade PD, Youlden DR, Cramb SM, Dunn J and Gardiner RA: Epidemiology of prostate cancer in the Asia-Pacific region. Prostate Int 1:47-58, 2013.
3. Freedland SJ: Screening, risk assessment and the approach to therapy in patients with prostate cancer. Cancer 117: 1123-1135, 2011.
4. Taiakina D, Dal Pra A and Bristow RG: Intratumoral hypoxia as the genesis of genetic instability and clinical prognosis in prostate cancer. Adv Exp Med Biol 772: 189-204, 2014.
5. Voss MJ, Niggemann B, Zänker KS and Entschladen F: Tumour reactions to hypoxia. Curr Mol Med 10: 381-386, 2010.
6. Jones BA, Beamer M and Ahmed S: Fractalkine/CX3CL1: A potential new target for inflammatory diseases. Mol Interv 10: 263-270, 2010.
7. Lucas AD, Bursill C, Guzik TJ, Sadowski J, Channon KM and Greaves DR: Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1). Circulation 108: 2498-2504, 2003.
8. Blaschke S, Koziolek M, Schwarz A, Benöhr P, Middel P, Schwarz G, Hummel KM and Müller GA: Proinflammatory role of fractalkine (CX3CL1) in rheumatoid arthritis. J Rheumatol 30: 1918-1927, 2003.
9. Tang L, Hu HD, Hu P, Lan YH, Peng ML, Chen M and Ren H: Gene therapy with CX3CL1/Fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma. Gene Ther 14: 1226-1234, 2007.
10. Faure S, Meyer L, Costagliola D, Vaneensberghe C, Genin E, Autran B, Delfraissy JF, McDermott DH, Murphy PM, Debré P, et al: Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science 287: 2274-2277, 2000.
11. Ludwig A, Hundhausen C, Lambert MH, Broadway N, Andrews RC, Bickett DM, Leesnitzer MA and Becherer JD: Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules. Comb Chem High Throughput Screen 8: 161-171, 2005.
12. Jamieson WL, Shimizu S, D'Ambrosio JA, Meucci O and Fatatis A: CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: Potential role in prostate cancer bone tropism. Cancer Res 68: 1715-1722, 2008.
13. Nevo I, Sagi-Assif O, Meshel T, Ben-Baruch A, Jöhrer K, Greil R, Trejo LE, Kharenko O, Feinmesser M, Yron I and Witz IP: The involvement of the fractalkine receptor in the transmigration of neuroblastoma cells through bone-marrow endothelial cells. Cancer Lett 273: 127-139, 2009.
14. Erreni M, Solinas G, Brescia P, Osti D, Zunino F, Colombo P, Destro A, Roncalli M, Mantovani A, Draghi R, et al: Human glioblastoma tumours and neural cancer stem cells express the chemokine CX3CL1 and its receptor CX3CR1. Eur J Cancer 46: 3383-3392, 2010.
15. Shulby SA, Dolloff NG, Stearns ME, Meucci O and Fatatis A: CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration and survival of human prostate cancer cells. Cancer Res 64: 4693-4698, 2004.
16. Lu Y, Cai Z, Galson DL, Xiao G, Liu Y, George DE, Melhem MF, Yao Z and Zhang J: Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate 66: 1311-1318, 2006.
17. Xiao LJ, Chen YY, Lin P, Zou HF, Lin F, Zhao LN, Li D, Guo L, Tang JB, Zheng XL and Yu XG: Hypoxia increases CX3CR1 expression via HIF-1 and NF-B in androgen-independent prostate cancer cells. Int J Oncol 41: 1827-1836, 2012.
18. Xiao LJ, Lin P, Lin F, Liu X, Qin W, Zou HF, Guo L, Liu W, Wang SJ and Yu XG: ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion. Int J Oncol 40: 1714-1724, 2012.
19. Hasegawa M, Sato S, Echigo T, Hamaguchi Y, Yasui M and Takehara K: Up regulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis. Ann Rheum Dis 64: 21-28, 2005.
20. Harbour JW, Luo RX, Dei Santi A, Postigo AA and Dean DC: Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 98: 859-869, 1999.
21. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
22. Nishimura S, Hato M, Hyugaji S, Feng F and Amano M: Glycomics for drug discovery: Metabolic perturbation in androgen-independent prostate cancer cells induced by unnatural hexosamine mimics. Angew Chem Int Ed Engl 51: 3386-3390, 2012.
23. Feldman BJ and Feldman D: The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34-45, 2001.
24. Borsig L, Wolf MJ, Roblek M, Lorentzen A and Heikenwalder M: Inflammatory chemokines and metastasis-tracing the accessory. Oncogene 33: 3217-3224, 2013.
25. Waugh DJ, Wilson C, Seaton A and Maxwell PJ: Multi-faceted roles for CXC-chemokines in prostate cancer progression. Front Biosci 13: 4595-4604, 2008.
26. Zhang S, Qi L, Li M, Zhang D, Xu S, Wang N and Sun B: Chemokine CXCL12 and its receptor CXCR4 expression are associated with perineural invasion of prostate cancer. J Exp Clin Cancer Res 27: 62, 2008.
27. Wang J, Lu Y, Wang J, Koch AE, Zhang J and Taichman RS: CXCR6 induces prostate cancer progression by the AKT/mammalian target of rapamycin signaling pathway. Cancer Res 68: 10367-10376, 2008.
28. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A and Schall T: A new class of membrane-bound chemokine with a CX3C motif. Nature 385: 640-644, 1997.
29. Koch AE: Chemokines and their receptors in rheumatoid arthritis: Future targets? Arthritis Rheum 52: 710-721, 2005.
30. Rimaniol AC, Till SJ, Garcia G, Capel F, Godot V, Balabanian K, Durand-Gasselin I, Varga EM, Simonneau G, Emilie D, et al: The CX3C chemokine fractalkine in allergic asthma and rhinitis. J Allergy Clin Immunol 112: 1139-1146, 2003.
31. Foussat A, Bouchet-Delbos L, Berrebi D, Durand-Gasselin I, Coulomb-L'Hermine A, Krzysiek R, Galanaud P, Levy Y and Emilie D: Deregulation of the expression of the fractalkine/fractalkine receptor complex in HIV-1-infected patients. Blood 98: 1678-1686, 2001.
32. Muehlhoefer A, Saubermann LJ, Gu X, Luedtke-Heckenkamp K, Xavier R, Blumberg RS, Podolsky DK, MacDermott RP and Reinecker HC: Fractalkine is an epithelial and endothelial cell-derived chemoattractant for intraepithelial lymphocytes in the small intestinal mucosa. J Immunol 164: 3368-3376, 2000.
33. Blum DL, Koyama T, M'Koma AE, Iturregui JM, Martinez-Ferrer M, Uwamariya C, Smith JA Jr, Clark PE and Bhowmick NA: Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy. Clin Cancer Res 14: 7790-7797, 2008.
34. Xu X, Wang Y, Chen J, Ma H, Shao Z, Chen H and Jin G: High expression of CX3CL1/CX3CR1 axis predicts a poor prognosis of pancreatic ductal adenocarcinoma. J Gastrointest Surg 16: 1493-1498, 2012.
35. Gaudin F, Nasreddine S, Donnadieu AC, Emilie D, Combadière C, Prévot S, Machelon V and Balabanian K: Identification of the chemokine CX3CL1 as a new regulator of malignant cell proliferation in epithelial ovarian cancer. PloS one 6: e21546, 2011.
36. Vermeulen K, Van Bockstaele DR and Berneman ZN: The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36: 131-149, 2003.
37. Malumbres M and Carnero A: Cell cycle deregulation: A common motif in cancer. Prog Cell Cycle Res 5: 5-18, 2003.
38. Golias CH, Charalabopoulos A and Charalabopoulos K: Cell proliferation and cell cycle control: A mini review. Int J Clin Pract 58: 1134-1141, 2004.
39. White GE, Tan TC, John AE, Whatling C, McPheat WL and Greaves DR: Fractalkine has anti-apoptotic and proliferative effects on human vascular smooth muscle cells via epidermal growth factor receptor signalling. Cardiovasc Res 85: 825-835, 2010.